Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

What Was Tested

In this not phased trial, researchers set out to test Semaglutide.

It had two arms (groups): Semaglutide/Rybelsus (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 22 actual participants took part.

It was open to men only aged from 18 years up to 60 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Healthy male volunteers aged 18-60 years. BMI 18.5-30 kg/m2. No regular medication.

The full record lists 3 inclusion and 5 exclusion criteria; among the exclusions: participation in a trial with investigational drugs within 30 days; vigorous physical exercise within 24 hours before the study participation; alcohol intake within 24 hours before the study participation.

How the Study Was Run

Design: randomized, crossover and triple-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Semaglutide and the comparison in turn, acting as their own control.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2025-01-16 with completion listed for 2025-10-31.

It ran at 1 site in Switzerland.

Its stated primary purpose is other.

What Was Measured

Primary outcome: Change in serum cortisol after Rybelsus vs. Placebo (time frame: within 210 minutes after the intake of the study drug).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Semaglutide in 22 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.